Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.

Neurology - 26 Feb 2002

Lee M S, Kim H S, Cho E K, Lim J H, Rinne J O

Abstract excerpt

OBJECTIVE: To investigate the relationship between the catechol-O-methyltransferase (COMT) genotype and the therapeutic efficacy of entacapone. METHODS: The efficacy of 2 months of entacapone treatment in 65 patients with PD with end-of-dose deterioration was studied. The efficacy of entacapone was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) score, the daily levodopa dosage, and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to Catechol O-Methyltransferase
Share to Catechols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chi-Square Distribution

Share to Double-Blind Method

Share to Enzyme Inhibitors

Share to Nitriles

Share to Parkinson Disease

Source

Identifiers

PMID: 11865133
DOI: 10.1212/wnl.58.4.564

Genes

COMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.PMID 11865133Read ↗

Catechol-O-methyl transferase (COMT) inhibitors in patients with Parkinson's disease: is COMT genotype a useful indicator of clinical efficacy?Semantic proximity Read ↗

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.Semantic proximity Read ↗

Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.Semantic proximity Read ↗

The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complicationsSemantic proximity Read ↗

Catechol-O-methyltransferase and Parkinson's disease.Semantic proximity Read ↗

Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.Semantic proximity Read ↗

Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease.Semantic proximity Read ↗

Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease.Semantic proximity Read ↗

The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's diseaseSemantic proximity Read ↗

Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease.Semantic proximity Read ↗

Association of daytime sleepiness with COMT polymorphism in patients with parkinson disease: a pilot study.Semantic proximity Read ↗

The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.